S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(-0.03%) $0.926
USD/NOK
(-0.05%) $10.84
USD/GBP
(-0.13%) $0.791
USD/RUB
(-0.09%) $92.49

Realtime updates for Satsuma Pharmaceuticals [STSA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated7 Jun 2023 @ 16:00

0.00% $ 1.100

Live Chart Being Loaded With Signals

Commentary (7 Jun 2023 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device...

Stats
Today's Volume 1.83M
Average Volume 1.11M
Market Cap 36.47M
EPS $0 ( 2024-03-26 )
Next earnings date ( $0 ) 2024-05-09
Last Dividend $0.200 ( 2014-03-28 )
Next Dividend $0 ( N/A )
P/E -0.553
ATR14 $0.0510 (4.64%)
Insider Trading
Date Person Action Amount type
2023-06-08 Ra Capital Management, L.p. Sell 5 914 252 Common Stock
2023-06-08 Ra Capital Management, L.p. Sell 10 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 20 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 30 000 Stock Option (Right to Buy)
2023-06-06 O'neil Thomas P. Sell 13 877 Common Stock, $0.0001 par value
INSIDER POWER
54.68
Last 97 transactions
Buy: 62 291 817 | Sell: 17 994 879

Volume Correlation

Long: 0.14 (neutral)
Short: 0.49 (neutral)
Signal:(60.819) Neutral

Satsuma Pharmaceuticals Correlation

10 Most Positive Correlations
NRBO0.956
DLTH0.937
NXTC0.934
TFFP0.933
TOI0.93
AGLE0.923
PRTK0.923
VIAV0.917
ONCS0.914
SGRP0.914
10 Most Negative Correlations
AGFS-0.944
APEN-0.938
PRDO-0.932
NRIM-0.92
FANH-0.916
VLYPO-0.916
UFPT-0.916
MACK-0.914
TSBK-0.91
AMRB-0.906

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Satsuma Pharmaceuticals Correlation - Currency/Commodity

The country flag -0.44
( neutral )
The country flag -0.15
( neutral )
The country flag 0.00
( neutral )
The country flag -0.48
( neutral )
The country flag 0.27
( neutral )
The country flag 0.28
( neutral )

Satsuma Pharmaceuticals Financials

Annual 2022
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-2.16
Q1 2023
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.300
Q4 2022
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.680
Q3 2022
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.470

Financial Reports:

No articles found.

Satsuma Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Satsuma Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A
Information
First Dividend $0.150 2012-12-19
Last Dividend $0.200 2014-03-28
Next Dividend $0 N/A
Payout Date 2014-04-15
Next Payout Date N/A
# dividends 7 --
Total Paid Out $1.500 --
Avg. Dividend % Per Year 0.00% --
Score 1.57 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-06-10)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
1.57
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-1.0861.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM1.3391.50010.0010.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM7.440.80010.008.00[1 - 3]
quickRatioTTM7.090.80010.008.00[0.8 - 2.5]
cashRatioTTM3.351.50010.0010.00[0.2 - 2]
debtRatioTTM0.00267-1.5009.96-10.00[0 - 0.6]
interestCoverageTTM107.961.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
freeCashFlowPerShareTTM-1.1172.00-0.559-1.117[0 - 20]
debtEquityRatioTTM0.00308-1.5009.99-10.00[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-318.091.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score3.51

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.7731.000-0.1790[1 - 100]
returnOnEquityTTM1.3392.501.15210.00[0.1 - 1.5]
freeCashFlowPerShareTTM-1.1172.00-0.372-1.117[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.005341.500-3.300[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-0.623

Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators